Source:http://linkedlifedata.com/resource/pubmed/id/16601244
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2006-7-24
|
pubmed:abstractText |
The clinical course of B-cell chronic lymphocytic leukemia (B-CLL) is variable, and novel biologic parameters need to be added to the clinical staging systems to predict an indolent or aggressive outcome. We investigated the 70-kDa zeta-associated protein (ZAP-70), CD38, soluble CD23 (sCD23), and cytogenetics in 289 patients with B-CLL. Both a shorter progression-free survival (PFS) and overall survival (OS) were observed in ZAP-70(+) (P < .001), in CD38(+) (P < .001) and in sCD23(+) patients (P < .001 and P = .013, respectively). ZAP-70(+)CD38(+) or ZAP-70(+) patients with an unmutated IgV(H) status showed both a shorter PFS (P < .001) and OS (P < .001 and P < .001, respectively) as compared with ZAP-70(-)/CD38(-) or ZAP-70(-) patients with mutated IgV(H) genes. Discordant patients showed an intermediate outcome. Note, ZAP-70(+) patients even if CD38(-) or mutated showed a shorter PFS, whereas ZAP-70(-) patients even if CD38(+) or unmutated had a longer PFS. Furthermore, ZAP-70 positivity was associated with a shorter PFS both within normal karyotype (P < .001) and within the poor-risk cytogenetic subset (P = .02). The predictive value of ZAP-70 expression was confirmed in multivariate analysis. Thus, ZAP-70 protein determined by flow cytometry improves the prognostic significance of cytogenetics and appears to be a better predictor of outcomes than IgV(H) gene mutational status. On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70(+) patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:AmadoriSergioS,
pubmed-author:BombenRiccardoR,
pubmed-author:BrunoAntonioA,
pubmed-author:BuccisanoFrancescoF,
pubmed-author:CantonettiMariaM,
pubmed-author:ConsalvoMaria Antonietta IrnoMA,
pubmed-author:DeganMassimoM,
pubmed-author:Del PoetaGiovanniG,
pubmed-author:Del PrincipeDomenicoD,
pubmed-author:Del PrincipeMaria IlariaMI,
pubmed-author:GatteiValterV,
pubmed-author:Lo CocoFrancescoF,
pubmed-author:MariniRitaR,
pubmed-author:MaurilloLucaL,
pubmed-author:MazzoneCarlaC,
pubmed-author:NiscolaPasqualeP,
pubmed-author:OttavianiLiciaL,
pubmed-author:PanettaPaolaP,
pubmed-author:SuppoGiovannaG,
pubmed-author:VendittiAdrianoA,
pubmed-author:ZucchettoAntonellaA,
pubmed-author:de FabritiisPaoloP
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
108
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
853-61
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:16601244-Adult,
pubmed-meshheading:16601244-Aged,
pubmed-meshheading:16601244-Aged, 80 and over,
pubmed-meshheading:16601244-Antigens, CD38,
pubmed-meshheading:16601244-Cytogenetic Analysis,
pubmed-meshheading:16601244-Female,
pubmed-meshheading:16601244-Flow Cytometry,
pubmed-meshheading:16601244-Gene Expression Regulation, Leukemic,
pubmed-meshheading:16601244-Humans,
pubmed-meshheading:16601244-Immunoglobulin Variable Region,
pubmed-meshheading:16601244-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:16601244-Male,
pubmed-meshheading:16601244-Middle Aged,
pubmed-meshheading:16601244-Mutation,
pubmed-meshheading:16601244-Predictive Value of Tests,
pubmed-meshheading:16601244-Prognosis,
pubmed-meshheading:16601244-Receptors, IgE,
pubmed-meshheading:16601244-ZAP-70 Protein-Tyrosine Kinase
|
pubmed:year |
2006
|
pubmed:articleTitle |
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.
|
pubmed:affiliation |
Cattedra di Ematologia, Università Tor Vergata, Ospedale S Eugenio, Via Fiume Giallo, 430 MA, 00144 Roma, Rome, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|